Equities

Embecta Corp

Embecta Corp

Actions
  • Price (USD)14.20
  • Today's Change0.00 / 0.00%
  • Shares traded382.90k
  • 1 Year change-49.19%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The Company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.

  • Revenue in USD (TTM)1.13bn
  • Net income in USD70.20m
  • Incorporated2021
  • Employees2.20k
  • Location
    Embecta Corp300 Kimball Drive, Suite 300PARSIPPANY NJ 07054United StatesUSA
  • Phone+1 (862) 401-0000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.embecta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orthofix Medical Inc760.05m-126.48m562.94m1.63k--0.9839--0.7407-3.40-3.4020.4215.240.83381.166.36465,143.80-13.87-8.88-16.48-10.9666.2072.37-16.64-9.281.19-8.380.194--62.0610.51-666.60--30.01--
Nano-X Imaging Ltd9.91m-60.78m566.33m164.00--2.90--57.18-1.08-1.080.17573.380.0419--8.0560,396.34-25.72-30.98-28.14-35.10-66.55---613.59-1,527.245.56--0.0175--15.47--46.33--114.35--
Varex Imaging Corp855.80m41.90m612.27m2.30k24.791.067.950.71540.6040.60416.1814.100.70081.945.50356,583.303.470.99134.031.1832.3931.704.951.362.372.570.4292--3.962.9359.0818.880.2924--
SI-Bone Inc144.05m-43.12m614.78m344.00--3.70--4.27-1.08-1.083.614.030.77281.626.44418,735.50-23.13-27.88-25.72-30.9478.1085.03-29.93-51.098.75--0.1791--30.5220.1929.25--52.62--
Paragon 28 Inc216.39m-47.84m635.41m430.00--3.57--2.94-0.5819-0.58192.642.150.72760.54845.77503,230.20-16.09---20.14--79.85---22.11--2.30-7.220.3832--19.30--28.94------
Fulgent Genetics Inc287.53m-165.95m661.63m1.18k--0.5849--2.30-5.57-5.579.6437.800.2206--6.01242,846.30-13.2916.70-14.1618.3737.4767.89-60.2529.06----0.00140.00-53.2768.41-217.03--57.08--
Orthopediatrics Corp161.83m-21.97m763.00m247.00--2.03--4.71-0.9647-0.96477.1115.740.37480.42475.13655,178.10-5.09-5.40-5.62-5.9374.0775.09-13.58-15.921.99--0.0271--21.6220.91-1,767.25--28.29--
Cytek Biosciences Inc200.79m-11.51m800.76m637.00--2.04--3.99-0.0856-0.08561.502.990.3951.444.30297,020.70-2.26---2.54--55.48---5.73--6.01--0.0086--17.67---571.58------
Atrion Corp176.67m18.72m818.82m712.0043.753.3823.914.6310.6310.63100.32137.460.67941.567.93248,127.807.2011.967.6312.6233.7741.9910.6019.053.06--0.0042.42-7.732.12-44.55-10.744.9811.27
Embecta Corp1.13bn70.20m832.02m2.20k11.88--7.860.73471.221.2219.62-13.350.942.5115.86514,772.705.83--8.06--65.57--6.20--1.791.511.89---0.7703---68.52------
Silk Road Medical Inc185.49m-53.42m874.87m474.00--5.94--4.72-1.37-1.374.763.730.72472.087.87391,322.80-20.87-29.02-22.75-32.9873.3172.91-28.80-46.849.62--0.34--27.7738.66-1.33---7.92--
Avanos Medical Inc680.10m-1.60m935.98m3.77k--0.76521.371.38-0.0315-1.3314.6226.650.40051.625.48180,350.00-0.0942-0.6527-0.1055-0.733856.3354.45-0.2353-1.601.474.850.1257---1.580.6357-146.05---18.37--
Perspective Therapeutics Inc-304.00k-48.91m939.51m116.00---------0.1622-0.197-0.0009---------2,620.69------------------------------------
Artivion Inc368.21m-9.58m979.09m1.50k--3.3271.852.66-0.2615-0.26158.647.070.47791.645.37245,470.70-1.25-2.20-1.33-2.3664.7565.51-2.61-5.344.262.260.5176--12.826.14-60.09--5.13--
BioLife Solutions Inc137.30m-62.93m1.01bn409.00--3.01--7.36-1.43-1.433.107.300.32382.175.61335,687.00-14.84-13.76-16.52-15.0432.9736.76-45.84-42.991.77-32.080.0717---11.4348.6552.49--86.35--
Data as of May 17 2024. Currency figures normalised to Embecta Corp's reporting currency: US Dollar USD

Institutional shareholders

62.63%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20248.52m14.80%
The Vanguard Group, Inc.as of 31 Mar 20247.09m12.32%
Millennium Management LLCas of 31 Dec 20233.64m6.32%
River Road Asset Management LLCas of 31 Mar 20243.45m5.99%
Yacktman Asset Management LPas of 31 Mar 20242.82m4.89%
American Century Investment Management, Inc.as of 31 Dec 20232.61m4.53%
SSgA Funds Management, Inc.as of 31 Dec 20232.52m4.37%
Fidelity Management & Research Co. LLCas of 31 Dec 20232.37m4.12%
Janus Henderson Investors US LLCas of 31 Dec 20231.72m2.99%
Charles Schwab Investment Management, Inc.as of 31 Mar 20241.33m2.30%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.